Plain-English translation of NCT07224321 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes Mellitus research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing Afrezza, an inhaled form of insulin, used together with a daily injection for teenagers who have just been diagnosed with type 1 diabetes. The study wants to see if this combination is safe and works well for managing blood sugar in young people. Researchers will also ask participants and their parents how satisfied they are with this treatment approach.
Most teenagers with type 1 diabetes use multiple insulin injections throughout the day. This trial explores whether using the medication as an inhaled option before meals—combined with one daily injection—might be easier for young people to stick with and give them better results.
You likely qualify if…
You likely don't qualify if…
You would use the inhaled medication before each meal (breakfast, lunch, and dinner) and take a daily insulin injection, with doses customized for your needs. The main study lasts 13 weeks, with check-ins to monitor your blood sugar levels, lung health, and how well the treatment is working. If it's going well, you can continue for an additional 26 weeks in an optional extension phase, and you and your parents will be asked about your satisfaction with the treatment.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States